In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

New insights from multicentre thrombolytic trials.

Session Pulmonary embolism: new therapeutic strategies

Speaker Stavros V Konstantinides

Event : ESC Congress 2013

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Embolism
  • Session type : Clinical Seminar

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two columns page  

Pulmonary embolism: new therapeutic strategies

Venous Thromboembolism

 

Low risk patients, identified by low clinical scores such as (s)PESI, should be considered for early discharge to home as their mortality on ambulatory anticoagulant treatment is <1%. Studies on new oral anticoagulants (dabigatran, rivaroxaban and apixaban) - as well as results of the Hokusai-VTE trial (edoxaban) revealed during this Congress offer a new quality of treatment, including lower bleeding risk, crucial in early discharged patients.

The optimal treatment strategy in patients at intermediate risk of early death, identified by more comprehensive laboratory cardiovascular assessment, is less clear.

New data from a large prospective randomized trial suggest that patients with RV dysfunction on imaging (echo or CT) and a positive troponin I or T test could benefit from treatment with thrombolysis to prevent early haemodynamic decompensation without, however, reducing all-cause mortality and at the cost of an increased risk of stroke.

Better stratification of bleeding risk, as well as safer thrombolytic regimens are necessary to implement such a strategy in clinical practice. The potential role of low dose and/or local thrombolysis, which could also be enhanced by application of therapeutic intravascular ultrasound, awaits further research.

References


Session Title: Pulmonary embolism: new therapeutic strategies

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are